Comparing ways to find Lynch syndrome in Vietnamese people with colorectal cancer
Compares PREMM5, MMRpredict and tumor screening for finding Lynch syndrome in colorectal cancer.
Plain-language title generated from the registry record
Registry title: Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam
Key facts
- Where
- Ho Chi Minh City, VietnamSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06863038, who can take part
Where in Vietnam
- University of Medicine and Pharmacy at Ho Chi Minh CityHo Chi Minh City, VietnamNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Medicine and Pharmacy at Ho Chi Minh City
- Trial code
- NCT06863038
- Record updated
- 7 March 2025
- Original description
This study evaluates the predictive value of PREMM5, MMRpredict models, and Universal Tumor Screening in detecting Lynch Syndrome in colorectal cancer (CRC) patients in Vietnam.Read full original descriptionShow less
Predictive Value of the PREMM5, MMRpredict Models, and the Universal Tumor Screening Strategy for Lynch Syndrome in Vietnam
This study evaluates the predictive value of PREMM5, MMRpredict models, and Universal Tumor Screening in detecting Lynch Syndrome in colorectal cancer (CRC) patients in Vietnam.
Vietnamese CRC patients (18-70 years) undergoing colonoscopy will be enrolled. Participants will complete a medical history questionnaire and provide blood samples for genetic testing. Tumor biopsy specimens will undergo Immunohistochemistry staining, BRAF V600E mutation, and MLH1 methylation analysis in case of loss of MLH1/PMS2 expression. Next-Generation Sequencing will detect germline MMR mutations, and biallelic somatic mutations will be analyzed if no germline mutations are found.
Inclusion: Aged 18 to 70 years; Provide informed consent to participate in the study; Undergo colonoscopy with endoscopic findings suspicious for CRC; Have biopsy-confirmed adenocarcinoma through colonoscopic biopsy.
Exclusion: Currently using anticoagulants or antiplatelet agents; Active gastrointestinal bleeding; History of coagulation disorders or difficulty controlling bleeding; Incomplete colonoscopy to the cecum (excluding cases of tumor-induced obstruction).